AVR Stock Forecast & Price Target

Anteris Technologies Glb is viewed favorably because DurAVR’s biomimetic, single-piece design appears to deliver materially better hemodynamics than competing TAVR valves, including low-8 mean gradients in small annuli versus low-to-mid teens for competitors and only 3% patient-prosthesis mismatch versus 40%+ for peer platforms. The bullish case is further strengthened by PARADIGM, the first head-to-head TAVR trial, with ~1,054 patients and secondary endpoints designed to validate superiority, while physician-led features like commissural alignment support valve-in-valve exposure that could reach ~30% of the TAVR market. Financially, AVR ended 2Q26 with $260.9M of cash, cash equivalents and restricted cash, and its 2Q26 R&D spending rose 34% quarter over quarter to $23.4M, signaling aggressive but well-funded execution.

Anteris Technologies Glb is facing a weak fundamental setup because its growth story depends on DurAVR gaining acceptance in a market where durability remains the key barrier, especially for younger and lower-risk patients, and where only 15-20% of severe aortic stenosis patients are currently treated. The company also faces material execution risk from PARADIGM trial outcomes and potential FDA delay on PMA approval, while it has already incurred significant operating losses and negative cash flow that raise concerns about future inoperability if expenses continue to rise. In addition, DurAVR lacks a proven marketing or sales strategy, and the exit from 4C Medical plus the planned need for 3-, 5-, and 10-year evidence underscore how limited near-term visibility remains.